Orphan Drugs Market Size, Trends, and Growth Strategies 2026-2033 The orphan drugs market is witnessing robust expansion driven by advancements in biotechnology and heightened focus on rare disease therapeutics. This industry is evolving rapidly, propelled by regulatory incentives and increasing R&D investments targeting niche patient populations, thereby reshaping the pharmaceutical landscape. Market Size and Overview The Global Orphan Drugs Market size is estimated to be valued at USD 175.4 billion in 2026 and is expected to reach USD 320.8 billion by 2033, exhibiting a compound annual growth rate (CAGR) of 9.3% from 2026 to 2033. https://www.coherentmarketinsights.com/market-insight/orphan-drugs-market-500

https://m2squareconsultancy.com/reports/rare-disease-drugs-market

https://www.databridgemarketresearch.com/reports/global-multi-omics-platforms-in-rare-disease-research-market

Global Gene Therapy Market to Reach USD 50.34 Billion by 2032 | CAGR 29.9% According to a newly published market research report by 24LifeSciences, global gene therapy market was valued at USD 8.40 billion in 2024 and is projected to reach USD 50.34 billion by 2031, growing at a compound annual growth rate (CAGR) of 29.9% during the forecast period 2025-2031. Gene therapy represents a revolutionary medical approach that involves modifying a persons genes to treat or prevent disease. It typically employs vectors, often engineered viruses, to deliver functional genetic material into cells to correct defective genes, regulate gene expression, or introduce new functions. While still an emerging field, its potential to provide durable, even curative, treatments for a range of genetic, oncologic, and rare diseases is driving unprecedented investment and innovation across the global healthcare sector. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/1604/gene-therapy-market-market